Systemic Mastocytosis: Response to the Efficacy of Cladribine(2-CdA) with Current Terminology and Approach.
作者信息
Yavaşoğlu Irfan, Turgutkaya Atakan
机构信息
Division of Hematology, Adnan Menderes University Medical Faculty, Aytepe Location, 09010 Efeler, Aydın Turkey.
出版信息
Indian J Hematol Blood Transfus. 2021 Apr;37(2):329-330. doi: 10.1007/s12288-020-01332-6. Epub 2020 Aug 31.
Abstract
摘要
相似文献
1
Systemic Mastocytosis: Response to the Efficacy of Cladribine(2-CdA) with Current Terminology and Approach.系统性肥大细胞增多症：采用当前术语和方法对克拉屈滨（2-氯脱氧腺苷）疗效的反应
Indian J Hematol Blood Transfus. 2021 Apr;37(2):329-330. doi: 10.1007/s12288-020-01332-6. Epub 2020 Aug 31.
2
Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. cladribine（2-CdA）在成年肥大细胞增多症患者中的长期疗效和安全性。
Blood. 2015 Aug 20;126(8):1009-16; quiz 1050. doi: 10.1182/blood-2014-12-614743. Epub 2015 May 22.
3
The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis.克拉屈滨（2-氯脱氧腺苷）治疗晚期系统性肥大细胞增多症的疗效
Indian J Hematol Blood Transfus. 2020 Oct;36(4):661-666. doi: 10.1007/s12288-020-01279-8. Epub 2020 Apr 15.
4
Cladribine therapy for systemic mastocytosis.克拉屈滨治疗系统性肥大细胞增多症。
Blood. 2003 Dec 15;102(13):4270-6. doi: 10.1182/blood-2003-05-1699. Epub 2003 Aug 21.
5
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.108例成人系统性肥大细胞增多症的减瘤治疗：α干扰素、羟基脲、甲磺酸伊马替尼或2-氯脱氧腺苷治疗期间的疗效分析及反应预测
Am J Hematol. 2009 Dec;84(12):790-4. doi: 10.1002/ajh.21561.
6
Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.成人系统性肥大细胞增生症：基于 342 例 Mayo 诊所患者和现有文献的预后和治疗综述。
Curr Opin Hematol. 2010 Mar;17(2):125-32. doi: 10.1097/MOH.0b013e3283366c59.
7
Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.干扰素α在系统性肥大细胞增多症中的应用。法国的经验及文献综述。
Pathol Biol (Paris). 2004 Jun;52(5):294-9. doi: 10.1016/j.patbio.2004.04.012.
8
Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine.用2-氯脱氧腺苷治疗系统性肥大细胞疾病。
Leuk Res. 2004 Feb;28(2):127-31. doi: 10.1016/s0145-2126(03)00185-1.
9
Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma.
Leuk Res. 2002 Nov;26(11):1043-6. doi: 10.1016/s0145-2126(02)00073-5.
10
Response to cladribine in patient with systemic mastocytosis.系统性肥大细胞增多症患者对克拉屈滨的反应。
Vojnosanit Pregl. 2011 May;68(5):444-6. doi: 10.2298/vsp1105444r.
本文引用的文献
1
The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis.克拉屈滨（2-氯脱氧腺苷）治疗晚期系统性肥大细胞增多症的疗效
Indian J Hematol Blood Transfus. 2020 Oct;36(4):661-666. doi: 10.1007/s12288-020-01279-8. Epub 2020 Apr 15.
2
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.MARS：晚期系统性肥大细胞增多症的突变调整风险评分。
J Clin Oncol. 2019 Nov 1;37(31):2846-2856. doi: 10.1200/JCO.19.00640. Epub 2019 Sep 11.
3
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.全身性肥大细胞增生症，第 2.2019 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2018 Dec;16(12):1500-1537. doi: 10.6004/jnccn.2018.0088.
4
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.梅奥联盟肥大细胞增多症预后系统：临床和混合临床-分子模型。
Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.
Zotero 插件